|
Market Closed -
Boerse Muenchen
16:44:02 2026-10-06 EDT
|
5-day change | 1st Jan Change | ||
| 0.5850 EUR | -3.31% |
|
-58.28% | - |
| 08-31 | Karyopharm Therapeutics Submits Supplemental New Drug Application to the Fda for Xpovio Plus Ruxolitinib for Patients with Myelofibrosis | CI |
| 08-29 | Karyopharm Therapeutics Inc. - Special Call |
Evolution of the Average Target: Karyopharm Therapeutics Inc.
Evolution of the Target Price: Karyopharm Therapeutics Inc.
Changes in Analyst Recommendations: Karyopharm Therapeutics Inc.
| Consensus | Analysts' recommendations evolution (4 months) | Financial estimates divergence | Analysts' Target price divergence | Objective/dr gap | ||
|---|---|---|---|---|---|---|
 | +16.25% | |||||
| +10.5% | |||||
| +4.93% | |||||
| +12.05% | |||||
| +7.67% | |||||
| +8.24% | |||||
| +34.74% | |||||
| -2.99% | |||||
| +9.7% | |||||
| Average | +11.23% | |||||
| Weighted average by Cap. | +11.85% |
Analysts' Consensus
Analyst Consensus Detail
Consensus revision (last 18 months)
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
- Stock Market
- Stocks
- KPTI Stock
- 25K0 Stock
- Consensus Karyopharm Therapeutics Inc.
Select your edition
All financial news and data tailored to specific country editions
